8.07.20
8 min. read

Nine thoughts on Teladongo. CPT sneak peek.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 064.

Get E&O weekly. | Subscribe
Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Hinge Health's plan to evolve into a virtual clinic and Livongo's diabetes prevention ramp up. Here's what's happening this week:

  • Three important posts below: 1) thoughts on the Teladongo merger. 2) a preview of the (many) digital health-related CPT codes the AMA editorial panel could greenlight this year. 3) breaking news that Proteus got zero bites at auction, so Otsuka will likely snag the assets for that low-low stalking horse bid.
  • CMS says virtual DPP still a no-go: In-person diabetes prevention programs (DPP) participating in the Medicare version of the program can offer virtual classes during the pandemic, but virtual DPP providers are still not allowed to participate in the Medicare program: "The MDPP expanded model was certified to provide in-person services
×
7.31.20
5 min. read

Hinge plans virtual MSK clinic. Livongo upping focus on DPP?

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 063.

Get E&O weekly. | Subscribe
Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Livongo's first year as a public company, dug into some never-ran digital health programs from UHG, and posted a new database of prescription-only, digital therapeutics that are in the collective DTx pipeline. Here's what's happening this week:

  • Rock Health and Natalist founder Halle Tecco posted a nostalgia-filled list of people who were working in digital health at the very beginning. I feel a little weird about being called a metaphorical grandfather of the industry at the age of 37, but, hey, I'll take it. Lots of worthwhile people to follow on Twitter in this thread.
  • Thanks for all the great feedback from subscribers on the Prescription DTx database, including ideas for new columns that will add more context (working on those now). I've since added a few
×
7.24.20
7 min. read

Livongo’s IPO anniversary. DTx pipelines.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 062.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about two UnitedHealth acquisitions, Bristol Myers Squibb's DTx timeline, and UHG's multiple mulligans in digital diabetes. Here's what's happening this week:

  • HHS re-re-confirmed yesterday that we are still in a public health emergency because of COVID--19, and this third declaration will also stay in effect for at least yet another 90 days.
  • Bristol Myers Squibb emailed me last week after the newsletter went out. They asked me to remove the launch timeline for their multiple myeloma digital therapeutic. I found that timeline (Q3 2020 launch) on a (somewhat) blinded job posting for the project, while similar job postings explicitly from BMS didn't provide as many details. BMS said their recruiting firm made a mistake and posted an inaccurate timeline, but wouldn't share the
×
7.17.20
7 min. read

Two UnitedHealth behavioral health acquisitions. BMS DTx launch Q3.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 061.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about PPP loan applications, Orexo's accelerated timeline, and a few curious clinical trial developments. Here's what's happening this week:

  • I heard from a reader who clarified that the AMA letter I mentioned last week re: their request for coverage of self-measured blood pressure monitoring was specifically about extending coverage to the connected BP devices themselves -- not the monitoring. I had it right, but I could have worded it better to stress that nuance.
  • In other policy news, CMS Administrator Seema Verma wrote an article that hinted at what's to come for telehealth and telemedicine coverage and accessibility post-pandemic. It reads as if: some telehealth will likely be restricted again (first-time visits for acute patients); payment will likely not stay at
×
7.10.20
6 min. read

265 PPP loans for digital health. Orexo Modia?

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 060.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Ostuka's initial $15 million bit for Proteus Digital Health's assets. Next week I've got something cooking, but open to more ideas -- send them my way. Here's what's happening this week:

  • I spent a few days digging into the federal government's just-released database of companies that applied for PPP loans earlier this year. I found more than 260 digital health companies listed (I'm sure there are more), including a few digital therapeutics companies. More on that below, but you can check out the E&O database of digital health PPP loan applicants right here.
  • In a letter to CMS this week, the AMA asked that CMS cover self-measured blood pressure monitoring as part of its extended coverage of remote patient monitoring CPT codes during the pandemic: "The AMA believes
×
7.01.20
6 min. read

What Otsuka bid for Proteus. Important DTx study begins.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 059.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about a secret JNJ acquisition and wondered if the VA confirmed that Google/Nest health project I wrote about last year. Next week I am open to ideas -- what should E&O dig into? Here's what's happening this week:

  • The 4th of July holiday is coming up this weekend in the USA, so E&O is coming at you a bit earlier in the week.
  • The FDA's digital health team is on a hiring spree. Is this prep for Pre-Cert? More here.
  • Still thinking about Apple adding sleep tracking to the Watch. I think it is a fair bet that Apple moves deeper into sleep health, into quasi-diagnostic territory as they did with AFib. First, their heart rate sensor was just for exercising, remember. I could see their sleep efforts evolving quickly and moving into FDA-regulated territory for a huge,
×
6.26.20
8 min. read

Secret JNJ health-tech acquisition. VA talks Nest Health?

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 058.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Proteus Digital Health's origins and bankruptcy. Next week I am open to ideas -- what should E&O dig into? Here's what's happening this week:

  • Plenty going on this week with Apple's WWDC event and the American Telemedicine Association's annual conference, but I also dug into a secret (not yet disclosed) J&J acquisition from last summer. If you've worked in digital health for a long time, it's a startup you probably know well... read on below.
  • Apple added sleep tracking and handwashing features to the Apple Watch along with more sophisticated movement tracking for Watch and iPhones. Apple also added more than a dozen new symptoms to its tracking features in HealthKit. Watch these sessions to learn more about the technical updates to various Apple Health-related
×
6.20.20
3 min. read

Preview of Proteus Report. Akili gets FDA OK (finally).

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 057.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Haven's health coaching partner going public. Next week I am open to ideas -- what should E&O dig into? Here's what's happening this week:

  • What a busy week. I pulled together The Proteus Digital Health Report after the long-running company filed for Chapter 11 bankruptcy on Monday. There's a bit more on that report below or just head to E&O to read the full 4,400-word report now.
  • The other big news this week: On Monday the FDA announced that it had (finally) granted Akili Interactive a De Novo clearance for EndeavorRx (AKL-T01), which is video game-based prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD). Perhaps the most remarkable thing about this move by the FDA is that its database shows it only took TWO MONTHS from the time
×
17 min. read

The Proteus Digital Health Report

In this article:

Proteus Digital Health, one of the original and highest-valued digital health companies, filed for Chapter 11 this week. This 4,400-word report digs into its mostly unreported origins, explores the company’s relationship with its biggest customer — Otsuka, uncovers the financial details of its recent deal with Tennessee’s Medicaid program, and considers what happens next for digital medicines.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

In 1989, Michael J. Fox reprised his role as Marty McFly for Back to the Future II (my favorite movie as a kid) and got everyone thinking about hoverboards and flying cars. Reagan bid farewell to the White House. Paula Abdul broke out with three hit singles. Seinfeld's TV sitcom premiered. The Berlin Wall fell.

That same year Dr. George Savage and Andrew Thompson had a conversation that would eventually lead to the founding of Proteus Biomedical.

So the story goes, anyway.

Proteus, one of the original and highest-valued digital health companies, filed for Chapter 11 this week. This 4,400-word report digs into its mostly unreported origins, explores the company's relationship with its biggest customer -- Otsuka, uncovers the financial details of its recent deal with Tennessee's Medicaid program, and considers what happens next for digital medicines.

Origins of Proteus Digital Health,

×
6.12.20
6 min. read

Haven’s health coach partner went public. French reimbursement.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 056.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote up how Apple's FDA clearances helped Alivecor go more directly-to-consumer. Next week I am open to ideas -- what should E&O dig into? Here's what's happening this week:

  • Happy to report I'll be the master of ceremonies for the first day of the American Telemedicine Association's annual conference (June 22-26), which will be online-only this year. The ATA gave me five (5) free passes for E&O subscribers -- $650 apiece usually -- so, the first five to reply will each get one (1). (Just give me a day or two to get back to you.)
  • CMS continues to confuse me this week as Administrator Seema Verma said: "It seems like it would not be a good thing to force our beneficiaries to go back to in-person visits." But a day later Verma affirmed: "But while telehealth has proven to be a
×